ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ViiV Healthcare Announces First Global Regulatory Approval
CABENUVA reduces treatment dosing days from 365 to 12 per year ​

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that Health Canada has approved CABENUVA, the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]). VOCABRIA oral tablets, to be used for short time periods in conjunction with CABENUVA, have also been approved by Health Canada. These approvals are the first for CABENUVA and VOCABRIA anywhere in the world.


CABENUVA allows virologically suppressed adults living with HIV to maintain viral suppression while reducing their dosing schedule from 365 days to 12 days per year. VOCABRIA and CABENUVA should not be used in patients with known or suspected resistance to cabotegravir or rilpivirine. A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry-leading portfolio centered on delivering innovative medicines for the HIV community.


Deborah Waterhouse, CEO, ViiV Healthcare, said: “Today’s approval marks a monumental step in the treatment of HIV and is a true testament to ViiV Healthcare’s R&D innovation. With CABENUVA, people living with HIV who are virologically suppressed now have an option to maintain that suppression with 12 treatments a year thereby positively impacting their lives.”


The approval of CABENUVA is based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies that included more than 1,100 participants from 16 countries.1,2 Prior to initiating treatment with CABENUVA, oral dosing of cabotegravir and rilpivirine lead-in was administered for approximately one month to assess the tolerability of cabotegravir and rilpivirine. The studies demonstrated that CABENUVA, when injected intramuscularly in the buttocks, once a month, was as effective as continuing their daily, oral, antiretroviral regimens in maintaining viral suppression throughout the 48-week study period.


In both studies, the most common adverse reactions (Grades 1 to 4) observed in ≥ 2% of participants receiving CABENUVA were injection site reactions, pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash, and diarrhoea. Over the 48-week study period, a total of 4% of participants discontinued CABENUVA due to adverse events.3 TheNew England Journal of Medicine published the 48-week results of these studies in its March 4, 2020 issue.


CABENUVA was preferred over their previous daily oral therapy by approximately 9 out of 10 patients who switched to cabotegravir and rilpivirine long-acting in ATLAS and FLAIR studies. Treatment preference data was collected from ATLAS and FLAIR clinical trial participants who received CABENUVA. In a pooled exploratory analysis of this Intent-to-Treat Exposed (ITT-E) population, 532 participants completed a single-item question at Week 48 (59 participants did not) and 88% (523/591) preferred CABENUVA compared with 2% (9/591) who preferred their previous ARV treatment. The results were descriptive in nature and are not intended to infer clinical significance.4


Chloe Orkin, M.D., Consultant Physician and Clinical Professor at Queen Mary University of London and FLAIR principal investigator, said: “CABENUVA, an injectable treatment, has the potential to transform HIV care by offering monthly instead of daily treatment to suitable patients. It reduces the frequency of dosing and is as effective as daily, oral, three-drug regimens in maintaining viral suppression among adults living with HIV. Most participants in the clinical trials preferred it over their prior oral daily regimens.”

Tags : #Viivhealthcare #Cabenuva #Hivdrug #Newapproval

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Fighting back against superbugs- A joint initiative by UK and India ResearchersMay 23, 2025
Archish Fertility & IVF Launches #RainbowBaby Campaign to Raise Miscarriage Awareness and Inspire HopeMay 22, 2025
Asian Hospital, Faridabad Becomes the First in the City to Launch Total Lab Automation with QuidelOrthoMay 22, 2025
Sharda Care Healthcity appoints Dr. Chirag Tandon as Director of Internal MedicineMay 22, 2025
Global Milestone in the Field of Robotic SurgeryMay 22, 2025
Medanta conducts advanced first aid training for Gurugram Traffic PoliceMay 22, 2025
When to Consult a Fertility Expert: Not Just After MarriageMay 22, 2025
Ovulation Tracking: A Doctor’s Guide to Doing It RightMay 22, 2025
Debunking IVF Myths: What Doctors SayMay 22, 2025
Aster CMI Hospital Becomes India’s Largest Pediatric Liver Transplant Program Under Affordable Transplant InitiativeMay 21, 2025
Point-of-care health technologies make a difference when deployed at point-of-needMay 21, 2025
Remidio Launches its new device ‘Pristine’, Innovating AI-Powered Eye Diagnostics with Dual Brand Strategy May 21, 2025
HCGMCC & SunAct Launch North Maharashtra’s 1st Centre Of Excellence In Cell & Gene TherapyMay 21, 2025
Transforming dementia support through technology networkMay 21, 2025
Endometriosis: The Pain You Shouldn’t IgnoreMay 21, 2025
The Best Age to Freeze Your Eggs — Doctor’s AdviceMay 21, 2025
Managing PCOS Without Birth Control: Fact or Fiction?May 21, 2025
Hormonal Acne in Women: It’s Not Just CosmeticMay 21, 2025
Is Spotting Between Periods Normal?May 21, 2025
QNET India Launches #BuzzForEarth Campaign on World Bee DayMay 20, 2025